0001185185-20-001618.txt : 20201116 0001185185-20-001618.hdr.sgml : 20201116 20201116164944 ACCESSION NUMBER: 0001185185-20-001618 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INVO Bioscience, Inc. CENTRAL INDEX KEY: 0001417926 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204036208 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39701 FILM NUMBER: 201317949 BUSINESS ADDRESS: STREET 1: 5582 BROADCAST COURT CITY: SARASOTA STATE: FL ZIP: 34240 BUSINESS PHONE: (978) 878-9505 MAIL ADDRESS: STREET 1: 5582 BROADCAST COURT CITY: SARASOTA STATE: FL ZIP: 34240 FORMER COMPANY: FORMER CONFORMED NAME: EMY'S SALSA AJI DISTRIBUTION COMPANY, INC. DATE OF NAME CHANGE: 20071108 10-Q 1 invobio20200930_10q.htm FORM 10-Q invobio20200930_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q 

 


 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020 

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

Commission file number 001-39701

 

INVO Bioscience, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

20-4036208

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

5582 Broadcast Court Sarasota, Florida, 34240

(Address of principal executive offices, including zip code)

 

 (978) 878-9505

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

 

Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

  

Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.0001 per share

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

INVO

The Nasdaq Stock Market LLC

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Shares of common stock, par value $.0001 per share:  4,954,019 shares outstanding as of November 16, 2020. 

 

 

 

INVO BIOSCIENCE, INC.

FORM 10-Q

FOR THE QUARTER ENDED September 30, 2020

 

TABLE OF CONTENTS

 

Item

 

Page Number

Part I

 

 

 

1.

Financial Statements (Unaudited):

3

 

Condensed Consolidated Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019

3

 

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (Unaudited)

 4

 

Condensed Consolidated Statements of Shareholders’ Deficiency for the three and nine months ended September 30, 2020 and 2019 (unaudited)

5

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (Unaudited)

6

 

Notes to the Condensed Consolidated Financial Statements (Unaudited)

7

2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

3.

Quantitative and Qualitative Disclosures about Market Risks

34

4.

Controls and Procedures

34

 

Evaluation of Disclosure Controls and Procedures

34

 

Changes in Internal Controls Over Financial Reporting

34

 

 

 

Part II

 

 

 

1.

Legal Proceedings

35

1A.

Risk Factors

35

2.

Unregistered Issuance of Equity Securities and Use of Proceeds

35

3.

Defaults Upon Senior Securities

35

4.

Mine Safety Disclosure

35

5.

Other Information

36

6.

Exhibits

36

 

Signatures

37

 

 

PART I.  FINANCIAL INFORMATION

 

Item 1.       Financial Statements

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   

September 30,

   

December 31,

 
   

2020

   

2019

 

ASSETS

 

(unaudited)

   

 (unaudited)

 

Current assets

               

Cash

  $ 908,289     $ 1,238,585  

Accounts receivable

    3,699       7,558  

Inventory

    241,484       101,387  

Prepaid expenses and other current assets

    218,667       195,910  

Total current assets

    1,372,139       1,543,440  
                 

Property and equipment, net of depreciation of $49,730 and $42,147 respectively

    106,000       93,055  
                 

Other assets:

               

Capitalized patents, net of amortization of $71,843 and $70,488 respectively

    5,879       7,234  

Lease right of use

    84,953       101,883  

Trademarks

    87,347       49,867  

Investment in joint ventures

    32,674       -  

Total other assets

    210,853       158,984  
                 

Total assets

  $ 1,688,992     $ 1,795,479  
                 

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

               

Current liabilities

               

Accounts payable and accrued liabilities, including related parties

  $ 455,978     $ 371,530  

Accrued compensation – related party

    532,592       393,017  

Deferred revenue, current portion

    714,286       714,286  

Current portion of lease liability

    22,356       21,365  

Notes payable

    157,620       -  

Income taxes payable

    -       912  

Total current liabilities

    1,882,832       1,501,110  
                 
                 
                 

Lease liability, net of current portion

    64,436       81,494  

Deferred revenue, net of current portion

    3,035,714       3,571,429  

Convertible notes, net of discount of $3,008,258 and $174,310 respectively

    607,521       325,784  

Convertible notes – related party, net of discount of $0 and $17,151 respectively

    -       28,824  

Deferred tax liability

    433       433  
                 

Total liabilities

    5,590,936       5,509,074  
                 
                 

Stockholders’ deficiency

               

Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

    -       -  

Common Stock, $.0001 par value; 200,000,000 shares authorized; 4,953,910 and 4,884,879 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

    495       489  

Additional paid-in capital

    24,525,427       20,174,682  

Accumulated deficit

    (28,427,866

)

    (23,888,766

)

Total stockholders’ deficiency

    (3,901,944

)

    (3,713,595

)

                 

Total liabilities and stockholders' deficiency

  $ 1,688,992     $ 1,795,479  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)  

 

   

For the Three

   

For the Three

   

For the Nine

   

For the Nine

 
   

Months Ended

   

Months Ended

   

Months Ended

   

Months Ended

 
   

September 30,

   

September 30,

   

September 30,

   

September 30,

 
   

2020

   

2019

   

2020

   

2019

 
                                 

Revenue:

                               

Product revenue

  $ 157,500     $ 125,000     $ 305,000     $ 615,927  

License revenue

    178,571       178,571       535,714       535,714  
                                 
                                 
                                 

Total Revenue

    336,071       303,571       840,714       1,151,641  
                                 

Cost of Goods Sold

    27,398       44,926       78,562       111,186  
                                 

Gross Margin

    308,673       258,645       762,152       1,040,455  
                                 
                                 

Research and development

    112,552       -       177,492       -  

Selling, general and administrative expenses

    1,463,887       891,008       4,311,872       2,087,725  

Total operating expenses

    1,576,439       891,008       4,489,364       2,087,725  
                                 

Loss from operations

    (1,267,766

)

    (632,363

)

    (3,727,212

)

    (1,047,270

)

                                 
                                 

Interest expense

    504,061       47,462       811,888       332,677  

Total other expenses

    504,061       47,462       811,888       332,677  
                                 

Loss before income taxes

    (1,771,827

)

    (679,825

)

    (4,539,100

)

    (1,379,947

)

                                 

Provision for income taxes

    -       (30,509

)

    -       (30,509

)

                                 

Net Loss

  $ (1,771,827

)

  $ (710,334

)

  $ (4,539,100

)

  $ (1,410,456

)

                                 

Basic net loss per weighted average shares of common stock

  $ (0.36

)

  $ (0.15

)

  $ (0.92

)

  $ (0.29

)

                                 

Diluted net loss per weighted average shares of common stock

  $ (0.36

)

  $ (0.15

)

  $ (0.92

)

  $ (0.29

)

                                 

Basic weighted average number of shares of common stock

    4,946,125       4,861,377       4,932,405       4,847,074  
                                 

Diluted weighted average number of shares of common stock

    4,946,125       4,861,377       4,932,405       4,847,074  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

(unaudited)

 

   

Common Stock

                         
   

Shares

   

Amount

   

Additional Paid-in Capital

   

Accumulated Deficit

   

Total

 
                                         

Balances, December 31, 2018

    4,821,641     $ 482     $ 18,996,517     $ (21,721,222

)

  $ (2,724,223

)

Common stock issued for services

    1,875       -       26,600       -       26,600  

Conversion of notes payable

    8,394       1       53,722       -       53,723  

Net loss for the three months ended March 31, 2019

    -       -       -       (458,570

)

    (458,570

)

Balances, March 31, 2019 (unaudited)

    4,831,910     $ 483     $ 19,076,839     $ (22,179,792

)

  $ (3,102,470

)

Conversion of Note payable

    28,907       3       184,997       -       185,000  

Net loss for the three months ended June 30, 2019

    -       -       -       (241,552

)

    (241,552

)

Balances, June 30, 2019 (unaudited)

    4,860,817     $ 486     $ 19,261,836     $ (22,421,344

)

  $ (3,159,022

)

Common stock issued for services

    1,562       -       15,000       -       15,000  

Common stock issued for settlement

    -       -       93,750       -       93,750  

Net loss for the three months ended 30, 2019

    -       -       -       (710,334 )     (710,334 )

Balances. September 20, 2019 (unaudited)

    4,862,379     $ 486     $ 19,370,586     $ (23,131,678 )   $ (3,760,606 )
                                         
                                         

Balances, December 31, 2019

    4,884,879     $ 489     $ 20,174,682     $ (23,888,766

)

  $ (3,713,595

)

Common stock issued to directors and employees

    40,569       4       303,459       -       303,463  

Common stock issued for services

    5,001       -       38,000       -       38,000  

Stock options issued to directors and employees as compensation

    -       -       381,475       -       381,475  

Net Loss for the three months ended March 31, 2020

    -       -       -       (1,444,392

)

    (1,444,392

)

Balances, March 31, 2020 (unaudited)

    4,930,449     $ 493     $ 20,897,616     $ (25,333,158

)

  $ (4,435,049

)

Common stock issued to directors and employees

    3,437       -       42,509       -       42,509  

Common stock issued for services

    3,750       1       22,799       -       22,800  

Stock options issued to directors and employees as compensation

    -       -       214,915               214,915  

Discount on convertible notes

    -       -       1,879,542       -       1,879,542  

Rounding shares as the result of reverse stock split

    24       -       -       -       -  

Net loss for the three months ended June 30, 2020

    -       -       -       (1,322,881

)

    (1,322,881

)

Balances, June 30, 2020 (unaudited)

    4,937,660     $ 494     $ 23,057,381     $ (26,656,039

)

  $ (3,598,164

)

Common stock issued to employees and directors

    12,500       1       54,702       -       54,703  

Common stock issued for services

    3,750       -       19,500       -       19,500  

Stock options issued to directors and employees as compensation

    -       -       255,797       -       255,797  

Discount on convertible notes payable

    -       -       1,244,363       -       1,244,363  

Stock issuance costs

    -       -       (106,316 )     -       (106,316 )

Net loss for the three months ended September 30, 2020

    -       -       -       (1,771,827 )     (1,771,827 )

Balances, September 30, 2020 (unaudited)

    4,953,910     $ 495     $ 24,525,427     $ (28,427,866 )   $ (3,901,944 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

   

For the Nine

   

For the Nine

 
   

Months Ended

   

Months Ended

 
   

September 30,

   

September 30,

 
   

2020

   

2019

 

Cash flows from operating activities:

               

Net loss

  $ (4,539,100

)

  $ (1,410,456

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

               

Non-cash stock compensation issued for services

    80,300       36,600  

Non-cash stock compensation issued to employees

    400,675       -  

Stock to be issued for legal settlement

    -       93,750  

Fair value of stock options issued to employees

    852,187       -  

Amortization of discount on notes payable

    465,525       297,058  

Amortization of discount on notes payable options

    59,324       -  

Amortization of discount on notes payable warrants

    71,430       -  

Amortization of discount on notes payable issuance costs

    81,764       -  

Amortization of leasehold right of use asset

    16,930       9,067  

Depreciation and amortization

    8,938       7,126  

Changes in assets and liabilities:

               

Accounts receivable

    3,859       198,878  

Inventory

    (140,097

)

    (25,817

)

Prepaid expenses and other current assets

    (22,757

)

    56,871  

Accounts payable and accrued expenses

    84,448       20,498  

Leasehold liability

    (16,067

)

    (8,456

)

Deferred revenue

    (535,715

)

    4,458,366  

Accrued interest

    34,870       (55,553 )

Accrued compensation

    139,575       (1,566,834

)

Income taxes payable

    (912

)

    30,509  

Net cash provided by (used in) operating activities

    (2,954,823

)

    2,141,607  
                 

Cash from investing activities:

               

Payments to acquire property, plant and equipment

    (20,528

)

    (64,839

)

Payments  to acquire trademarks

    (37,480

)

    (49,867 )

Investment in joint venture

    (32,674 )     -  

Net cash (used in) investing activities

    (90,682

)

    (114,706

)

                 

Cash from financing activities:

               

Proceeds from the sale of notes payable

    2,998,905       -  

Proceeds from notes payable

    157,620       -  

Principal payments on notes payable - related parties

    (40,000

)

    (97,743

)

Principal payment on notes payable

    (295,000

)

    (131,722

)

Payment of stock issuance expenses

    (106,316 )     -  

Net cash provided by (used in) financing activities

    2,715,209       (229,465

)

                 

Increase (decrease) in cash and cash equivalents

    (330,296 )     1,797,436  
                 

Cash and cash equivalents at beginning of period

    1,238,585       212,243  
                 

Cash and cash equivalents at end of period

  $ 908,289     $ 2,009,679  
                 

Supplemental disclosure of cash flow information:

               
                 

Cash paid during the period for:

               
                 

Interest

  $ 83,134     $ 84,043  
                 

Taxes

  $ 1,062     $ 912  
                 

Leasehold right of use asset and leasehold liability upon adoption of ASU 2016-02, lease (Topic 842)

  $ -     $ 116,441  
                 

Common stock issued upon note payable and accrued interest conversion

  $ -     $ 238,723  
                 

Common stock issued for prepaid services

  $ -     $ 5,000  
                 

Beneficial conversion feature on convertible notes

  $ 1,208,163     $ -  
                 

Fair value of shares issued with debt

  $ 868,985     $ -  
                 

Fair value of warrants issued with debt

  $ 999,464     $ -  
                 

Fair value of warrants issued related to debt placement

  $ 47,293     $ -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 1 – Basis of Presentation

 

The accompanying unaudited condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, the condensed consolidated statements of operations and stockholders’ deficiency for the three and nine months ended September 30, 2020 and 2019,  and condensed consolidated statement of cash flows for the nine months ended September 30, 2020 and 2019 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.

 

The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31,2019 previously filed by the Company with the Securities and Exchange Commission (“SEC”) on March 30, 2020.

 

The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of September 30, 2020, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

 

Note 2 – Recent Accounting Pronouncements

 

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification.

 

The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations.

 

Recently Adopted Accounting Pronouncements 

 

In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement.  The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements. 

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 3 – Going Concern

 

On January 14, 2019, the Company entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) which granted Ferring an exclusive licensing rights to sublicense the Company’s patented INVOcell together with the retention device for the U.S. market. Under the terms of the Distribution Agreement, Ferring made an initial cash payment to the Company of $5,000,000 upon the execution of the Ferring distribution agreement in January 2019. 

 

For the nine months ended September 30, 2020 and 2019, the Company had net losses of $4,539,100 and $1,410,456, respectively. The Company had a working capital deficit of $510,693 as of  September 30, 2020, compared to working capital of $42,330 as of December 31, 2019. As of September 30, 2020, the Company’s stockholder’s deficiency was $3,901,944 compared to $3,713,595 as of December 31, 2019 and cash used in operations was $2,954,823 for the nine months ended September 30, 2020 compared to cash provided by operations of $2,141,607 for the nine months ended September 30, 2019. Those factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Based on the Company’s projected cash needs, it will be dependent on generating sufficient sales, entering into new distribution agreements, or raising additional debt or equity capital to support the Company’s plans over the next 12 months.   

 

Note 4 – Inventory

 

As of September 30, 2020, and December 31, 2019, the Company recorded the following inventory balances:

 

   

September 30,

2020

   

December 31,

2019

 

Raw Materials

  $ 99,363     $ 44,333  

Work in Process

    14,823       55,502  

Finished Goods

    127,298       1,552  

Total Inventory

  $ 241,484     $ 101,387  

 

Note 5 – Property and Equipment

 

The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of September 30, 2020 and December 31, 2019:

 

 

Estimated Useful Life

Manufacturing equipment

6 to 10 years

Medical equipment

10 years

Office equipment

3 to 7 years

 

   

September 30,

2020

   

December 31,

2019

 

Manufacturing Equipment

  $ 132,513     $ 132,513  

Medical equipment

    20,528       -  

Office equipment

    2,689       2,689  

Less: Accumulated Depreciation

    (49,730

)

    (42,147

)

Total

  $ 106,000     $ 93,055  

 

During the three months ended September 30, 2020 and 2019, the Company recorded depreciation expense of $2,528 and $2,527, respectively.

 

During the nine months ended September 30, 2020 and 2019, the Company recorded depreciation expense of $7,583 and $3,703, respectively.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 6 – Patents

 

As of September 30, 2020, and December 31, 2019, the Company recorded the following patent balances:

 

   

September 30,

2020

   

December 31,

2019

 

Total Patents

  $ 77,722     $ 77,722  

Accumulated Amortization

    (71,843

)

    (70,488

)

Patent costs, net

  $ 5,879     $ 7,234  

 

During the three months ended September 30, 2020 and 2019, the Company recorded $452 and $1,455, respectively, in amortization expenses related to patents.

 

During the nine months ended September 30, 2020 and 2019, the Company recorded $1,355 and $3,423, respectively, in amortization expenses related to patents.

 

Estimated amortization expense as of September 30, 2020 is as follows:

 

Years ended December 31,

       

2020 – remaining three months

  $ 454  

2021

    1,809  

2022

    1,809  

2023 and thereafter

    1,807  

Total

  $ 5,879  

 

As of September 30, 2020, and December 31, 2019, the Company recorded the following trademarks balances:

 

   

September 30,

2020

   

December 31,

2019

 

Total Trademarks

  $ 87,347     $ 49,867  

Trademarks

  $ 87,347     $ 49,867  

 

The increase in the trademark assets of $37,480 was the result of additional legal fees.

 

The trademarks have an indefinite life, so no amortization expense is calculated. Trademarks are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable.  The Trademark assets were created in 2019, and no material adverse changes have occurred since their creation.

 

Note 7 – Leases

 

The Company has an operating lease for its facility, which has a remaining term of 5 years with an option to renew for three additional years. They also do not have an early termination clause included. The Company’s operating lease agreements does not contain any material restrictive covenants.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

As of September 30, 2020, the Company's lease components included in the consolidated balance sheet were as follows:

 

Lease component

Classification

 

September 30, 2020

 

Assets

         

ROU assets - operating lease

Other assets

  $ 84,953  
           

Total ROU assets

  $ 84,953  
           

Liabilities

         

Current operating lease liability

Current liabilities

  $ 22,356  
           

Long-term operating lease liability

Other liabilities

    64,436  
           

Total lease liabilities

  $ 86,792  

 

Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following:

 

   

Nine months ended

 
   

September 30, 2020

 

Operating lease costs

  $ 18,924  

Short term lease cost

    -  
         

Total rent expense

  $ 18,924  

 

Future minimum lease payments under non-cancellable leases were as follows:

 

   

September 30, 2020

 

2020 - remaining three months

  $ 6,088  

2021

    24,839  

2022

    25,585  

2023

    26,352  

2024

    8,870  

Total future minimum lease payments

  $ 91,734  

Less: Interest

    (4,942 )

Total operating lease liabilities

  $ 86,792  
         

Current operating lease liability

  $ 22,356  

Long-term operating lease liability

    64,436  

Total operating lease liabilities

  $ 86,792  

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 8 – Notes Payable

 

Notes Payable

 

In August 2016, the Company converted a long-time vendor’s outstanding accounts payable balance of $131,722 into a promissory note with a three year term that accrues interest at 5% per annum. The note provided for interest-only payments on the first and second anniversaries of the note. The note was payable in full along with any outstanding accrued interest on August 9, 2019 The Note and all accrued interest were paid in full on January 25, 2019 and as of September 30, 2020, the balance is $0.  The interest on this note for the nine months ended September 30, 2019 was $489.

 

2018 Convertible Notes Payable

 

In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrued interest at the rate of 9% per annum which was payable in stock. The 2018 Convertible Notes in an aggregate principal amount of $550,000, were due on January 30, 2020, and 2018 Convertible Notes with an aggregate principal amount of $345,000 were due on March 31, 2021. The notes were convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes could elect to convert the notes in shares of the Company’s common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 32,982 shares of common stock. During the nine months ended September 30, 2019, 2 note holders converted principal and accrued interest of $235,000 and $3,723, respectively, into a total of 37,301 shares of common stock.

 

At inception of issuance, the Company calculated a beneficial conversion feature of the 2018 Convertible Notes in the form of a discount of $895,000; In May 2020, the remaining balance of $396,044, which included the principal balance of $420,000, accrued interest of $94,419, and the conversion discount of $118,375, was repaid. As part of the extinguishment of the 2018 Convertible Notes, the Company issued 2020 Convertible Notes (as described below) to two remaining holders in the amount of $143,640. The remaining balance related to these notes was $116,693, which was comprised of a principal balance of $125,000, accrued interest of $23,318, net of the remaining discount of $31,625. In accordance with ASC 470, the extinguishment for these two holders was accounted for as a modification and no gain or loss was recorded. In May 2020, the remaining balance of $35,483, which included the principal balance of $40,000, accrued interest of $7,355, and a conversion discount of $11,872, was repaid. As of September 30, 2020, the balance of the 2018 Convertible Notes is $0.

 

2020 Convertible Notes Payable

 

From May 2020 through July 2020, the Company issued convertible notes (the “2020 Convertible Notes”) payable to investors in the aggregate principal amount of approximately $3.5 million. The 2020 Convertible Notes accrue interest at the rate of 10% per annum and are due in November, December 2021and January 2022. The Company calculated a beneficial conversion feature of approximately $1,208,163 and also incurred professional fees of approximately $371,000 related to this issuance resulting in a total discount related to these two items of approximately $1,579,163. The notes are convertible into shares of common stock at an exercise price of $5.76 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2020 Convertible Notes can elect to convert the principal and any accrued but unpaid interest on the notes into shares of the Company’s common stock at a price equal to the price per share paid in such subsequent equity financing.

 

In connection with the issuance of the 2020 Convertible Notes, the Company also issued 303,623 unit purchase options to purchase 303,623 units at an exercise price of $8.00 per unit, with each unit consisting of one share of common stock and one warrant to purchase common stock at an exercise price of $9.60 per share. The units and warrants are exercisable for a period of five years from the date of issuance, are subject to a downward provision if the Company issues securities at a lower price, and warrant holders have a right to require the Company to pay cash in the case of a fundamental transaction. In accordance with ASC 815, the warrants and options issued in this period were determined to require equity treatment.

 

In connection with the recent convertible note private placement, INVO agreed to issue to the placement agent and the selling agent five-year warrants to purchase 6,750 shares of the Company’s  common stock at an exercise price of $5.76.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Of the $3.5 million in net proceeds received in the offering at September 30, 2020, $2.2 million was allocated to the unit purchase options issued to investors based on their relative fair value. This amount represented a discount on the debt and additional paid-in-capital at the date of issuance.

 

Principal balances of the 2020 Convertible Notes were as follows:

 

   

September 30,

2020

   

December 31,

2019

 
                 

2020 Convertible Notes

    3,494,840       -  

Accrued interest

    120,939       -  

Less beneficial conversion feature discount

    (934,769

)

    -  

Less options discount

    (809,649

)

    -  

Less warrants discount

    (974,669

)

    -  
                 

Less issuance cost

    (289,171

)

    -  

Total, net of discount

  $ 607,521     $ -  

 

Interest expense on the 2020 Convertible Note was $89,158 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $120,939 and $0 of interest expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

Amortization of options discount on the 2020 Convertible note was $43,769 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $59,334 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

Amortization of warrant discount on the 2020 Convertible Note was $52,688 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $71,430 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

Amortization of beneficial conversion feature on the 2020 Convertible Note was $257,455 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $274,064 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

Amortization of issuance costs on the 2020 Convertible Note was $61,187 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $81,764 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

On July 1, 2020, the Company received a loan in the principal amount of $157,620 relating to the U.S. Small Business Administration’s Paycheck Protection Program. The loan will mature 18 months from the date of funding is payable over 18 equal monthly installments, and bears interest at a rate of 1% per annum. The loan is forgivable up to 100% of the principal balance based upon satisfaction of certain criteria under the Paycheck Protection Program.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2019

(unaudited)

 

Note 9 – Notes Payable and Other Related Party Transactions

 

In April 2011, the Company issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate.  The Company paid $25,000 of the Note in 2011 in cash. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.96 per share, subject to adjustments. During the three and nine months ended September 30, 2019, the Company accrued interest in the amount of $597 and $1,836 on the Q211 Note, respectively.

 

In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000.  The Q411 Note carries a 10% interest rate. The Q411 Note was converted into common stock of the Company at a conversion price of $0.32 per share, subject to adjustments.  During the three and nine months ended September 30, 2019, the Company accrued interest in the amount of $253 and $749 on the Q411 Note, respectively.

 

The foregoing notes had maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum,    compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.96 and $.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.21).

 

On August 7, 2019, the Company sent James Bowdring, a related party, a check in the amount of $65,197 as full payment of the foregoing promissory notes. On August 8, 2019, Mr. Bowdring’s legal counsel returned this check with a letter stating that the check did not properly account for the compound interest identified in such notes.  In addition, the letter stated Mr. Bowdring’s desire to convert these promissory notes into shares of the Company’s common stock in lieu of any cash payment.  The Company does not believe that Mr. Bowdring has the right to convert such notes upon receiving payment of such notes and intends to vigorously contest any conversion of these notes. 

 

In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of the Company’s common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the three months ending September 30, 2020 and 2019, $0 and $907 of interest was accrued, respectively. In addition, $1,380 and $2,692 of interest was accrued in the nine months ended September 30, 2020 and 2019, respectively.

 

In May 2018, the Company sold 4,687 shares of common stock at a price of $6.40 per share for proceeds of $30,000 to Charles Mulrey and family, the brother-in-law of Robert J. Bowdring, Director & Acting Chief Financial Officer as part of the recent financing.

 

During the second quarter of 2018, INVO Bioscience settled a commitment it had with one of its Directors, Dr. Kevin Doody for the services he and his team performed prior to and following INVOcell’s FDA clearance related to clinical guidance and support. The Company issued him 93,750 common shares of stock with a fair value of $1,530,000.

 

The Company previously rented its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of former Director and former Interim CFO, Robert Bowdring from November 2012 through May 2019 when the Company relocated to a new facility. It was a month to month rental arrangement for less than the going fair market real estate rental rate. The rent expense paid for the nine months ended September 30, 2020 and 2019 was $0 and $1,800 respectively. In addition, the Company had purchased stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as the Company’s former corporate office. INVO Bioscience spent $0 and $2,134 with Superior during the three months ended September 30, 2020 and 2019, respectively, spent $0 and $8,168 during the nine months ended September 30, 2020 and 2019, respectively. 

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Principal balances of the related party loans were as follows:

 

   

September 30,

2020

   

December 31,

2019

 
                 

James Bowdring Family – 2018 Convertible Notes

    -       45,975  

Less discount

    -       (17,151

)

Total, net of discount

  $ -     $ 28,824  

 

Interest expense on related party loans was $0 and $1,271 for the three months ended September 30, 2020 and 2019, respectively. In addition, $1,380 and $4,792 of interest expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. 

 

Accounts payable and accrued liabilities balances include accrued directors fees, expenses reports for management and employees for expenses they paid for personally related to travel or normal business expenses. 

 

   

September 30,

   

December 31,

 
   

2020

   

2019

 

Accounts payable and accrued liabilities

  $ 5,756     $ 13,018  

 

Note 10 – Stockholders’ Equity

 

Reverse Stock Split

 

On December 16, 2019, the Company’s stockholders approved a reverse stock split at a ratio of between 1-for 5 and 1-for-25, with discretion for the exact ratio to be approved by the Company’s board of directors. On February 19, 2020, the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 1-for-20. On May 21, 2020, the Company filed a certificate of change (with an effective date of May 26, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock. The reverse split took effect at the open of business on May 26, 2020.

 

On October 22, 2020 the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 5-for-8 and also approved a proportionate decrease in the Company’s authorized common stock to 125,000,000 shares from 200,000,000. Pursuant to Nevada Revised Statutes, a company may effect a reverse split without stockholder approval if both the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced as a result of the reverse split, the reverse split does not adversely affect any other class of stock of the company, and the company does not pay money or issue scrip to stockholders who would otherwise be entitled to receive a fractional share as a result of the reverse split. On November 5, 2020, the Company filed a certificate of change (with an effective date of November 9, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 5-for-8 reverse stock split of its outstanding common stock. On November 6 , 2020, the Company received notice from FINRA/OTC Corporate Actions that the reverse split would take effect at the open of business on November 9, 2020 and the reverse stock split took effect on that date.

 

During the three months ended September 30, 2020 we incurred $106,316 of offering costs related to issuance of common stock.

 

Nine Months Ended September 30, 2020

 

In January 2020, the Company issued 31,250 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $221,400 to an officer.

 

In February 2020, the Company issued 3,125 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $24,750 to an employee of which $14,438 was amortized in the nine months ended September 30, 2020.

 

In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member.

 

In February 2020, the Company issued 1,875 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $15,000 for services.

 

In February 2020, pursuant to Section 4(a)(2) of the Securities Act of 1933 as amended (the “Securities Act”), the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered.  The Company did not receive any proceeds from the issuance.

 

In March 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance.

 

In May 2020, pursuant to Section 3(a)(9) of the Securities Act, the Company issued 24 shares of common stock as the result of the rounding on the reverse stock split.  The Company did not receive any proceeds from the issuance.

 

In May 2020, the Company issued 3,438 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,930 to an employee of which $12,804 was amortized in the nine months ended September 30, 2020.

 

In June 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $22,800 in consideration of consulting services rendered.  The Company did not receive any proceeds from the issuance.

 

In August 2020, the Company issued 12,500 shares of restricted stock under its 2019 Stock Incentive Plan with a fair value of $72,200 to an employee of which $12,032 was amortized in the nine months ended September 30, 2020.

 

In August 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $19,500 in consideration of consulting services rendered.  The Company did not receive any proceeds from the issuance.

 

Nine Months Ended September 30, 2019

 

In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,875 shares of common stock with a fair value of $26,600 to service providers.

 

In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 8,394 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. 

 

In April 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 25,000 shares of common stock for conversion of notes payable in the amount of $160,000.

 

In May 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,907 shares of common stock for conversion of notes payable in the amount of $25,000.

 

In August 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,562 shares of common stock with a fair value of $15,000 to service providers.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 11 – Stock Options and Warrants

 

Equity Incentive Plans

 

In October 2019, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan"). Under the 2019 Plan, the Company’s Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to its employees, directors, and consultants. The 2019 Plan initially provided for the issuance of 500,000 shares. However, in January 2020, under the terms of the plan, the number of available shares issuable increased to 793,093 shares as the aggregate number of shares under the Plan automatically increases on January 1st of each year, in an amount equal to six percent (6%) of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year.

 

Options generally have a life of 3 to 10 years and exercise price equal to or greater than the fair market value of the Common Stock as determined by the Company’s Board of Directors.

 

Vesting for employees typically occurs over a three-year period or based on performance objective.

 

The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of the Company’s Common Stock on the OTCQB Market on the respective dates.

 

   

Options Outstanding

   

Options Exercisable

 
   

Number of

Shares

   

Price per

Share Range

   

Weighted

Average

Exercise

Price

   

Aggregate

Intrinsic

Value (1)

   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Aggregate

Intrinsic

Value (1)

 

Balance at December 31, 2019

    260,018     $ 8.16-9.25     $ 8.41     $ -       11,256     $ 8.16     $ -  

Forfeited

    -     $ -     $ -       -       -       -       -  

Vested

    -       -       -       -       140,399       6.48       -  

Exercised

    -     $ -     $ -       -       -       -       -  

Granted

    328,303     $ 5.76-8.32     $ 6.47       -       -       -       -  

Balance at September 30, 2020

    588,321     $ 5.76-9.25     $ 7.32     $ -       151,655     $ 7.16     $ -  

 

(1)

The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.

 

The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

 

   

Nine Months ended September 30,

 
   

2020

   

2019

 

Risk-free interest rate range

    0.48 to 1.65

%

    -

%

Expected life of option-years

    5.20 to 5.77       -  

Expected stock price volatility

    110.8 to 128.0

%

    -

%

Expected dividend yield

    -

%

    -

%

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executives, within the Company. The Company does not currently pay dividends on its common stock nor does it expect to do so in the foreseeable future.

 

           

Options Outstanding

   

Options Exercisable

 
   

Range of

Exercise Prices

   

Options

Outstanding

   

Weighted

Average

Remaining

Life in

Years

   

Weighted

Average

Exercise

Price

   

Options

Exercisable

   

Weighted

Average

Exercise

Price of

Options

Exercisable

 

Year ended December 31, 2019

  $ 8.16-9.25       260,018       2.6     $ 8.41       11,256     $ 8.16  

Nine Months ended September 30, 2020

  $ 5.76-9.25       588,321       3.7     $ 7.32       151,655     $ 7.16  

 

   

Total Intrinsic Value of

Options Exercised

   

Total Fair Value of

Options Vested

 

Year ended December 21, 2019

    -       69,787  

Nine months ended September 30, 2020

  $ -     $ 910,444  

 

For the nine months ended September 30, 2020, the weighted average grant date fair value of options granted was $5.44 per share. The Company estimates the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through September 30, 2020, the weighted average remaining service period is 3.7 years.

 

The Company recognized $259,547 and $0 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the three months ended September 30, 2020 and 2019, respectively. In addition, the Company recognized $852,187 and $0 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the nine months ended September 30, 2020 and 2019, respectively. Unamortized stock option expense at September 30, 2020 that will be amortized over the weighted-average remaining service period totaled $2,107,857.

 

Restricted Stock and Restricted Stock Units

 

In the nine months ended September 30, 2020, the Company issued 90,412 shares of restricted stock, to certain employees and directors. Shares issued to employees and directors are generally either vest at grant or vest over a period of one year from grant. In the nine months ended September 30, 2020, 50,871 shares of restricted stock vested.

 

The following table summarizes the Company’s aggregate restricted stock awards and restricted stock unit activity during the nine months ended September 30, 2020:

 

   

Number of

Unvested Shares

   

Weighted Average

Grant Date Fair Value

   

Aggregate Value

of Unvested Shares

 
                         

Balance at December 31, 2019

    10,417     $ 9.60     $ 100,000  

Granted

    56,509     $ 6.98     $ 394,280  

Vested

    (50,871

)

  $ 7.63     $ (388,173

)

Forfeitures

    (-

)

  $ -     $ (-

)

Balance at September 30, 2020

    16,055     $ 6.61     $ 106,107  

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

The Company recognized $67,202 and $388,173 in stock-based compensation expense for the three and nine months ended September 30, 2020, respectively. It will recognize $106,107 over the remaining requisite service period. Stock-based compensation expense is recorded in selling, general and administrative expenses on the consolidated statement of operations

 

In October 2019, the Company issued 12,500 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $120,000 to an officer, of which $90,000 was amortized in the nine months ended September 30, 2020.

 

Warrants

 

In connection with the issuance of the 2020 Convertible Notes, the Company also issued 310,373 unit purchase options to purchase 310,373 units at an exercise price of $8.00 per unit, with each unit consisting of one share of common, and a warrant to purchase one share of common stock at an exercise price of $9.60 per share. The units and warrants are exercisable for a period of five years from the date of issuance and are subject to a downward provision if the Company issues securities at a lower price. Warrant holders have a right to require the Company to pay cash in the event of a fundamental transaction. In accordance with ASC 815, the warrants and options issued in this period were determined to require equity treatment and $868,973 related to the options and $998,818 related to warrants was recorded in equity in the nine months ended September 30, 2020.

 

In connection with the issuance of the 2020 Convertible Notes, the Company agreed to issue the placement agent and the selling agent five-year warrants to purchase 6,750 shares of the Company’s common stock at an exercise price of $5.76. In the nine months ended September 30, 2020, $47,293 was recorded in equity related to these warrants.

 

A Monte Carlo model was used because the investor warrants and options contain fundamental transaction payouts and reset events that cannot be modeled with a Black Scholes model.

 

The fair value of the options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions:

 

   

Nine Months ended September 30,

 
   

2020

   

2019

 

Risk-free interest rate range

    0.33% - 0.39

%

    -

%

Stock Price

 

$3.00 - $3.95

      -

%

Expected life of warrants and option (years)

    5.00       -

%

Expected stock price volatility

    108.2% - 112.5

%

    -

%

Expected dividend yield

    0

%

    -

%

 

The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options and warrants. Expected volatility is based upon the historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The options and warrants are valued assuming projected reset events adjusting the exercise price and a forced exercise upon a projected fundamental transaction by management. The options and warrants early exercise are modeled assuming registration after 180 days. We do not currently pay dividends on our common stock nor do we expect to in the foreseeable future.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 12 – Income Taxes

 

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future.  Currently, a valuation allowance is established for all DTA’s and carryforwards as their recoverability is deemed to be uncertain. If the Company’s expectations for future operating results at the federal or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, it may need to adjust the valuation allowance, for all or a portion of the Company’s deferred tax assets. The Company’s income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in the Company’s  valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company’s future earnings.

 

Income tax expense was $0 and $30,509 for the nine months ended September 30, 2020 and 2019. The annual forecasted effective income tax rate for 2020 is 0% with a year-to-date effective income tax rate for the three and nine months ended September 30, 2020 respectively of 0%.

 

Note 13 – Commitments and Contingencies

  

A)

Litigation

 

INVO Bioscience, Inc. v. James Bowdring

 

On August 7, 2019, the Company sent James Bowdring, the brother of the Company’s then Chief Financial Officer, a check in the amount of $65,197 as full and final payment under those certain promissory notes dated April 8, 2011 and November 9, 2011.  On August 8, 2019, Mr. Bowdring’s legal counsel returned the check.  A basis for returning the check was a claim that the interest due under the Notes called for compounded interest and not per annum interest.  In addition, the letter rejecting the tender of the payment in full check alleged Mr. Bowdring was considering a future intention to convert his Promissory Notes into shares of the Company’s common stock.  Mr. Bowdring, through his counsel, indicated that such future intention to convert the Notes to common stock were contingent upon Mr. Bowdring addressing certain personal issues which were not disclosed by his counsel in the correspondence returning the checks.  The Company does not believe that Mr. Bowdring has the right to seek conversion of the Notes once payment for the Notes has been tendered.  In order to resolve the issue of the Company’s tender of payment in full versus Mr. Bowdring’s assertion that he can reject tender and seek conversion, the Company has filed an action in the Suffolk Superior Court in Boston on September 3, 2019 seeking Declaratory Judgment and Judgment for Breach of Contract. On September 30, 2019, Mr. Bowdring filed an answer and counterclaim under which he alleged breach of contract, fraud, promissory estoppel, unfair and deceptive practices and constructive trust. Mr. Bowdring is seeking receipt of all shares due under the adjusted conversion price.

 

The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance.  Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $0.96 and $0.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.2100).

 

The Company does not currently expect the above matter to have a material adverse effect upon either the Company’s results of operations, financial position, or cash flows.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

B)

Employee Agreements

 

On October 10, 2019, the Company entered into an agreement with its CEO, Steve Shum. The Company agreed to pay Mr. Shum an annual salary of $260,000. In addition, Mr. Shum is eligible to earn bonus compensation of up to $75,000 bonus upon a successful up-listing to the NASDAQ exchange. All other bonus amounts will be determined by the Board of Directors, in their sole discretion. In addition to his base salary and performance bonus, the Company granted Mr. Shum: (i) 12,500 shares of common stock and (ii) a three-year option to purchase 202,599 shares of common stock at an exercise price of $8.16 per share. These options will vest monthly over a 3-year period.

 

On January 15, 2020, the Company entered into an employment agreement (the “Employment Agreement”) with Michael Campbell to continue serving as the Company’s Chief Operating Officer and Vice President of Business Development, a position he has held since February 2019. Mr. Campbell’s compensation will consist of an annual base salary of $220,000, and a target annual incentive bonus of up to 50% of his base salary if the Company achieves goals and objectives determined by the board of directors.

 

In connection with the Employment Agreement, on January 17, 2020, the Company granted Mr. Campbell 31,250 shares of Company common stock, and an option to purchase 125,000 shares of Company common stock (the “Option”) at an exercise price of $6.84 per share. One quarter of the Option vested upon grant, and the remainder vests in monthly increments over a period of two years from the date of grant.

 

The Company has entered into a consulting agreement with Shine Management, Inc. through which it is receiving outsourced accounting and the support of its acting CFO, Debra Hoopes. Debra is the CFO and Chief Administrative Officer of Shine Management, Inc. and Management Services Company in Charlottesville, VA.

 

Note 14 – Contracts with Customers

 

The Company has adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.

 

Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is shipped from the Consignor to the customer.

 

In January 2019, the Company announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that the Company believes will allow it to implement its overall business plan. The Company believes that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide it with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today. The agreement calls for the issuance of an initial upfront payment of $5,000,000 which the Company received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide the Company with a source of non-dilutive financing to execute the Company’s plan. Under the terms of the agreement the Company can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. The Company believes this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace. The initial upfront payment of $5,000,000 which the Company received upon the signing of the agreement is being recognized to income over the 7 year term.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the licensed product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five day label enhancement from the FDA for the current incubation period for the licensed product at least three (3) years prior to the expiration of the term of the license for the licensed product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement.  The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the licensed product during the final two years of the initial term.

 

The Ferring license was deemed to be a functional license that provide customers with a “right to access” to the Company’s intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the three months and nine months ended September 30, 2020, the Company recognized $178,572 and $357,143, respectively, related to the Ferring license agreement.

 

As of September 30, 2020, and December 31, 2019, the Company had deferred revenues of $3,750,000 and $4,285,715, respectively.

 

On September 20, 2019, the Company entered into an exclusive distribution agreement with Quality Medicines, Cosmetics & Medical Equipment Import for the territories of Sudan, Uganda and Ethiopia. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. Quality Medicines is required to register the Company’s product in each of these countries. We expect to renew or extend this agreement for another year.

 

On September 11, 2019, the Company entered into an exclusive distribution agreement with G-Systems Limited registered in Nigeria. In the territories of Nigeria. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. G-Systems is required to register the Company’s product in Nigeria. We expect to renew or extend this agreement for another year.

 

On November 12, 2019, the Company announced that it had entered into exclusive distribution agreements with Biovate a Jordanian company for the territory of Jordan and Orcan Medical for the territory of Turkey. This agreement has a term of one year with extensions by mutual agreement. Safadi Drugstore is required to register the Company’s product in Jordan. We expect to renew or extend this agreement for another year.

 

On January 16, 2020, the Company announced a Joint Venture agreement for the India market. Under terms of the agreement, The Company and its partner, Medesole Healthcare and Trading Pvt Ltd, will each own 50% of the joint venture. The Company provides the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows the Company to benefit not only from the sale of the device, but from the delivery of the entire solution. The Company believes this JV structure is an attractive new model for us, and one in which the Company may replicate in other select parts of the world. As of September 30, 2020 the final JV setup had not yet been completed.

 

Sources of Revenue

 

The Company has identified the following revenues disaggregated by revenue source:

 

Domestic Physicians  – direct sales of products concluded in January 2019 

Domestic Distributor - sales to Ferring who then sells to physicians

Domestic Licensing fee

International Distributors  – direct sales of products.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

For the nine months ended September 30, 2020 and 2019 the source of revenue was derived from:

 

   

September 30,

2020

   

September 30,

2019

 

Domestic Product revenue

  $ 305,000     $ 615,927  
                 

Domestic licensing fee

    535,714       535,714  
                 

Total revenue

  $ 840,714     $ 1,151,641  

 

The Company’s revenue is highly concentrated as 100 percent of revenue is currently derived from the Company’s agreement with Ferring.

 

Contract Balances

 

The Company incurs agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, the Company has determined that the balance related to these obligations is generally immaterial at any point in time. The Company monitors the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

 

Warranty

 

The Company’s general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Commissions and Contract Costs

 

The Company does not use or offer sales commissions of any type at this time. The Company generally does not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

 

Practical Expedients

 

The Company’s payment terms for sales direct to customers and distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

  

Shipping and Handling Charges

 

Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products.

 

Taxes Collected from Customers

 

As the Company’s products are used in another service and are exempt, the Company does not collect taxes. If the Company were to collect taxes, they would be assessed on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

 

Effective Date and Transition Disclosures

 

Adoption of the new standards did not have a material impact on the Company’s consolidated financial statements and is not expected to have a material impact in future periods.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(unaudited)

 

Note 15 – Investment in Joint Ventures

 

Effective September 24, 2020, the Company’s wholly owned subsidiary, INVO Centers, LLC a Delaware limited liability company (“INVO Centers”) entered into a Pre-Incorporation and Shareholders Agreement (the “Agreement”) with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez” together with INVO and Arredondo, the “Shareholders”) under which INVO Centers, Arredondo and Ramirez intend to commercialize the INVO IVC procedure and offer related medical treatments in Mexico (the Business”) and to further become shareholders in a Mexican company to be incorporated in Mexico (the “Mexico Company”) for purposes of operating the Business. For the nine months ended September 30, 2020 the Company has invested $23,517 in this joint venture.

 

The Mexico Company, which will be named Positib Fertility, S.A. de C.V, is to be established within three weeks of executing the Agreement, with each of INVO Centers, Arredondo and Ramirez to be equal shareholders (1/3 each).  The Mexico Company will acquire exclusively from INVO Bioscience, Inc. the INVOcell product to be used by the Mexico Company to render its services at cost plus any uncured shipping, customs and related fees. The joint venture partners have begun the process to identify key personnel, started the build out, and have requested approval from Cofepris (the Mexico Ministry of Health). The Company believes that, the earliest possible operational timeframe for the joint venture is second quarter of 2021.

 

The Shareholders agree that the Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company board of directors and Shareholders. In addition, the Shareholders agree that the Mexico Company will be the exclusive distributor of INVO Bioscience, Inc. and affiliates with respect to the INVO Products in Mexico and the Shareholders agree not to compete directly or indirectly with the Mexico Company in Mexico. Each Shareholder agreed to certain restrictions on transfer of its equity in the Mexico Company and afforded the other Shareholders a right of first refusal prior to any transfer.

 

In addition, the Company has invested $9,157 in joint ventures the Company is currently exploring.

 

Note 16 – Subsequent Events

 

The Company issued 109 rounding shares in conjunction with the reverse stock split of the Company’s common stock at a ratio of 5-for-8.

 

On November 12, 2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as representative of the several underwriters (the “Underwriters”), in connection with the Company’s public offering (the “Offering”) of 3,625,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a public offering price of $3.20 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 45 days, to purchase up to an additional 543,750 shares of Common Stock at the public offering price, less underwriting discounts and commissions (the “Option Shares,” and together with the Firm Shares, the “Shares”).

 

The Company expects to close the sale of the Common Stock on November 17, 2020, subject to customary closing conditions. The net proceeds to the Company from the Offering are expected to be approximately $10.1 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

 

The Company has evaluated subsequent events through the date the financial statements were released and there were no others.

 

 

 

 

 

Item 2.       Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Certain statements made in this Quarterly Report on Form 10-Q, including without limitation this Management’s Discussion and Analysis of Financial Condition and Results of Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These forward-looking statements may sometimes be identified by such words as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue” or similar words.  We believe that it is important to communicate our future expectations to investors.  However, these forward-looking statements involve many risks and uncertainties including those referred to herein and in our Annual Report on Form 10-K for the year ended December 31, 2019.  Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors.  Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

 

Overview

 

We are a medical device company focused in the Assisted Reproductive Technology (“ART”) marketplace. Our mission is to increase access to care and expand fertility treatment and patient care across the globe. Our patented device, the INVOcell, is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. INVOcell was granted FDA clearance in the United States in November 2015, received the CE mark in October 2019, and is now positioned to help provide millions of infertile couples across the globe access to a new infertility treatment option. We believe this novel device and procedure provides a more natural, safe, effective and economical fertility treatment compared to current infertility treatments, including in-vitro fertilization (“IVF”) and intrauterine insemination (“IUI”). Unlike conventional infertility treatments such as IVF where the eggs and sperm develop into embryos in a laboratory incubator, the INVOcell utilizes the women’s vaginal cavity as an incubator to support a more natural fertilization and embryo development environment.

 

In both current utilization of the INVOcell and in clinical studies, the INVO Procedure has shown to have equivalent pregnancy success and live birth rates as the traditional assisted reproductive technique, IVF. Additionally, we believe there are psychological benefits of the potential mother’s participation in fertilization and early embryo development by vaginal incubation compared to that of traditional IVF treatment. INVOcell also offers to patients a more natural and personalized way to achieve pregnancy.

 

For many couples struggling with infertility, access to treatment is often not available. Financial challenges (cost of treatment) and limited availability (or capacity) of fertility medical care are two of the main challenges in the ART marketplace that contribute to the large percentage of untreated patients. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have a baby. We believe INVOcell can address many of the key challenges in the ART market, particularly patient cost and infrastructure capacity constraints. The many benefits to the INVO Solution include:

 

● 

Cost: Many current clinics offering INVOcell are doing so at approximately half the cost of IVF treatment, due to: less drugs often being prescribed for INVOcell, fewer office visits needed, less laboratory time needed as incubation is occurring inside the body rather than the lab incubator.

 

● 

Enhances Industry capacity: The INVOcell device eliminates the need for a lab incubator as well as helps reduce the overall need for lab-support resources. We believe this generally supports the ability to lower costs as well as enable a clinic to handle a higher volume of patients on average.

● 

Reduces the risk of errors of wrong embryo transfers since the embryos are never separated from the woman.

● 

Promotes greater involvement by couples in the treatment and conception.

● 

Creates a more natural and environmentally stable incubation than traditional IVF incubation in a laboratory.

 

In the second quarter of 2016, the first US baby from the INVOcell and INVO procedure following FDA clearance was born in Texas.

 

 

 

In January 2019, we entered into a Distribution & Supply Agreement with Ferring International Center S.A. (“Ferring”), pursuant to which, among other things, we granted Ferring an exclusive license in the United States (the “Territory”) with rights to sublicense under patents related to our proprietary INVOcell™ intravaginal culture device together with the retention device and any other applicable accessories (collectively, the “licensed product”) to market, promote, distribute and sell the licensed product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including infertility treatment) in humans (the “Field”). Ferring is responsible, at its own cost, for all commercialization activities for the licensed product in the United States. We retained a limited exception to the exclusive license granted to Ferring allowing us, subject to certain restrictions, to establish up to five clinics that will commercialize INVO cycles in the Territory. We are looking at the best approach to pursue establishing these five Company-owned INVO-only clinics. We retained all commercialization rights for the licensed product outside of the United States. We believe the strategic partnership with a strong reproductive organization such as Ferring  has provided us with the necessary sales and marketing resources and overall market credibility to help execute our goal to expand the INVOcell device around the world.

 

On September 20, 2019, we entered into an exclusive distribution agreement with Quality Medicines, Cosmetics & Medical Equipment Import for the territories of Sudan, Uganda and Ethiopia. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. Quality Medicines is required to register our product in each of these countries. We expect to renew or extend this agreement for another year.

 

On September 11, 2019, we entered into an exclusive distribution agreement with G-Systems Limited registered in Nigeria. In the territories of Nigeria. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. G-Systems is required to register our product in Nigeria. We expect to renew or extend this agreement for another year.

 

On November 12, 2019, we announced we had entered into exclusive distribution agreements with Biovate a Jordanian company for the territory of Jordan and Orcan Medical for the territory of Turkey. This agreement has a term of one year with extensions by mutual agreement. Safadi Drugstore is required to register our product in Jordan. We expect to renew or extend this agreement for another year.

 

On January 16, 2020, we announced a Joint Venture agreement for the India Market. Under terms of the agreement, INVO Bioscience and our Partner, Medesole Healthcare and Trading Pvt Ltd, will each own 50% of the joint venture. We provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows INVO to benefit not only from the sale of the device, but from the delivery of the entire solution. We believe this JV structure is an attractive new model for us, and one in which we may replicate in other select parts of the world. 

 

We operate with a core internal team and outsource certain operational functions in order to help accelerate our efforts as well as reduce fixed internal overhead needs and in-house capital equipment requirements.  Our most critical management and leadership functions are carried out by our core management team. We have contracted out the manufacturing, assembly, packaging, labeling and sterilization of the device to a medical manufacturing company  and to a sterilization specialist to perform the gamma sterilization process.  

 

Historically, our most significant challenge in growing our business has been our limited resources.   In prior years we had reduced this by, among other things, officers and directors foregoing salaries and fees and not engaging in certain activities in order to avoid incurring certain expenses (such as travel and marketing costs).  Beginning in 2019, as a result of the Ferring agreement and upfront payment, we expanded our sales and marketing efforts and regulatory and clinical development activities. Our cash needs are primarily attributable to funding our sales and marketing efforts, strengthening our training capabilities, satisfying existing obligations, funding our clinical trial for additional product indications, building an administrative infrastructure, and costs and professional fees associated with being a public company.  We currently expect our existing distribution and partnership agreements, such as that with Ferring and the other more recent agreements with non-U.S. companies, provide for increased revenue minimums and will help offset the higher level of spending.

 

 

Recent Developments

 

On October 22, 2020, our board of directors approved a reverse stock split of our common stock at a ratio of 5-for-8 and also approved a proportionate decrease in the Company’s authorized common stock to 125,000,000 shares from 200,000,000. Pursuant to Nevada Revised Statutes, a company may effect a reverse split without stockholder approval if both the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced as a result of the reverse split, the reverse split does not adversely affect any other class of stock of the company, and the company does not pay money or issue scrip to stockholders who would otherwise be entitled to receive a fractional share as a result of the reverse split,  On November 5, 2020, we filed a certificate of change with the Nevada Secretary of State (with an effective date of November 9, 2020) pursuant to Nevada Revised Statutes 78.209 to (i) decrease the number of authorized shares of common stock from 200,000,000 to 125,000,000 shares and (ii) effectuate a 5-for-8 reverse stock split of the outstanding common stock. On November 6, 2020, we received notice from FINRA/OTC Corporate Actions that the reverse split would take effect at the open of business on November 9, 2020 and the reverse stock split took effect on that date

 

Effective September 24, 2020, our wholly owned subsidiary, INVO Centers, LLC a Delaware limited liability company (“INVO Centers”) entered into a Pre-Incorporation and Shareholders Agreement (the “Agreement”) with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez” together with INVO and Arredondo, the “Shareholders”) under which INVO Centers, Arredondo and Ramirez intend to commercialize the INVO IVC procedure and offer related medical treatments in Mexico (the Business”) and to further become shareholders in a Mexican company to be incorporated in Mexico (the “Mexico Company”) for purposes of operating the Business. For the nine months ended September 30, 2020 we have invested $23,517 in this joint venture.

 

The Mexico Company, which will be named Positib Fertility, S.A. de C.V, is to be established within three weeks of executing the Agreement, with each of INVO Centers, Arredondo and Ramirez to be equal shareholders (1/3 each).  The Mexico Company will acquire exclusively from INVO Bioscience, Inc. the INVOcell product to be used by the Mexico Company to render its services at cost plus any uncured shipping, customs and related fees. The joint venture partners have begun the process to identify key personnel, started the build out, and have requested approval from Cofepris (the Mexico Ministry of Health).   We believe, the earliest possible operational timeframe for the joint venture is the second quarter of 2021.

 

The Shareholders agree that the Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company board of directors and Shareholders.  In addition, the Shareholders agree that the Mexico Company will be the exclusive distributor of INVO Bioscience, Inc. and affiliates with respect to the INVO Products in Mexico and the Shareholders agree not to compete directly or indirectly with the Mexico Company in Mexico.  Each Shareholder agreed to certain restrictions on transfer of its equity in the Mexico Company and afforded the other Shareholders a right of first refusal prior to any transfer.

 

From May 15, 2020 through September 30 2020, we entered into definitive securities purchase agreements (“Purchase Agreements”) with accredited investors for their purchase of (i) secured convertible notes issued by us in the aggregate original principal amount of 3,494,840 (the “Notes”), and (ii) Unit Purchase Options (“Purchase Options”) to purchase 430,017 units (each, a “Unit”), at an exercise price of $6.00 per Unit (subject to adjustments), with each Unit exercisable for (A) one share of our Common Stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $9.60 (subject to adjustments) (the “Private Placement”). Each purchaser of a Note will be issued a five-year Purchase Option to purchase 0.086875 Units for each dollar of Notes purchased. We received gross proceeds of approximately $3.15 million (of which $2,950,000 was received in cash and $143,640 resulted from cancellation of indebtedness). Tribal Capital Markets, LLC acted as placement agent (the “Placement Agent”) in the Private Placement. We paid the Placement Agent and certain selling agents a cash fee of 8% on a portion of the proceeds for an aggregate amount of $236,000. We also agreed to issue the Placement Agent and the selling agent 5-year warrants to purchase 6,750 shares of our common stock at an exercise price of $5.76. These warrants will have the same terms and conditions as the Warrants issued in the Private Placement, except for the different exercise price. We received approximately $3.05 million in net proceeds from the Private Placement, after deducting placement agent fees and selling agent fees payable to the Placement Agent and selling agent, respectively, and investor counsel in connection with the transaction. We used approximately $413,456, in proceeds to repay outstanding 9% promissory notes and we intend to use the remaining proceeds for working capital and general corporate purposes.

 

Pursuant to that certain Form of Secured Convertible Note entered into in connection with the Purchase Agreement (the “Form of Note”), interest on such Notes accrues at a rates of ten percent 10% per annum and is payable either in cash or in shares of the Company’s common stock at the conversion price in the Note on each of the six and twelve month anniversaries of the issuance date and on the maturity dates of November 15, 2021; December 22, 2021 and December 30, 2021. The Notes issued in July 2020 have a Maturity Date of January 1, 2022.

 

 

All amounts due under the Notes are convertible at any time after the issuance date, in whole or in part (subject to rounding for fractional shares), at the option of the holders into our common stock at a fixed conversion price, which is subject to adjustment as summarized below. The Notes are initially convertible into our common stock at an initial fixed conversion price of $3.60 per share. This conversion price is subject to adjustment for stock splits, combinations or similar events and anti-dilution provisions, among other adjustments.

 

Upon any issuance by us of any of our equity securities, including Common Stock, for cash consideration, indebtedness or a combination thereof after the date hereof (a “Subsequent Equity Financing”), each holder shall have the option to convert the outstanding principal and accrued but unpaid interest of its Note into the number of fully paid and non-assessable shares of securities issued in the Subsequent Equity Financing (“Conversion Securities”) equal to the product of unpaid principal, together with the balance of unpaid and accrued interest and other amounts payable hereunder multiplied by 1.1, divided by the price per share paid by the investors for the Conversion Securities.

 

A Note may not be converted, and shares of common stock may not be issued under the Notes if, after giving effect to the conversion or issuance, the holder together with its affiliates would beneficially own in excess of 9.99% of our outstanding ordinary shares.

 

We may prepay the Notes at any time in whole or in part by paying a s sum of money equal to 100% of the principal amount to be redeemed, together with accrued and unpaid interest plus a prepayment fee equal to one percent (1%) of the principal amount to be repaid.

 

The Notes contain customary triggering events including but not limited to: (i) failure to make payments when due under the Notes; and (ii) bankruptcy or insolvency of the Company. If a triggering event occurs, each holder may require us to redeem all or any portion of the Notes (including all accrued and unpaid interest thereon), in cash.

 

The Notes are secured by the proceeds from the $3,000,000 milestone payment pursuant to Section 7.2(b) of the Distribution Agreement between the Company and Ferring, after such proceeds are actually received by us from Ferring, all pursuant to the terms of a Security Agreement entered into between us and the noteholders under the Purchase Agreement.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of financial condition and results of operations are based upon the unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles as recognized in the United States of America. The preparation of these financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosure of contingent assets and liabilities.  Our estimates include those related to revenue recognition, the valuation of inventory, and valuation of deferred tax assets and liabilities, useful lives of intangible assets, warranty obligations and accruals.  We base our estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances.  Actual results may differ from these estimates under different assumptions or conditions.  For a complete description of accounting policies, see Note 1 to our financial statements included in our Form 10K for the year ended December 31, 2019.  There were no significant changes in critical accounting estimates.

 

 

Results of Operations

 

Three months ended September 30, 2020, compared to the three months ended September 30, 2019

 

Net Sales and Revenues

 

Revenue for the three months ended September 30, 2020, was $336,071 compared to $303,571 for the three months ended September 30, 2019. The increase of $32,500 or 11% was the result of an increase in product sales to Ferring.  Many clinics have resumed operations since the early year lockdowns associated with COVID-19, although we believe at a more measured pace compared to pre-COVID levels. That resumption of activities aided our third quarter progress and we believe this, along with Ferring’s required annual minimums, should contribute to an even stronger fourth quarter sales figure.

 

Gross Margin

 

The gross margin reported for the three months ended September 30, 2020 was 92% or $308,673 compared to 85% or $258,645 for the three months ended September 30, 2019. 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three months ended September 30, 2020 were $1,463,887 compared to $891,008 for the three months ended September 30, 2019. The increase of $572,879 or 64% from 2020 was primarily the result of an increase in personnel expenses, stock-based compensation and other corporate expenses.  Non-cash related operating expenses in the period totaled $330,548.

 

Research and Development Expenses

 

We began to fund additional research and development (“R&D”) efforts in 2020 in for our clinical trial, anticipated to occur in 2020, and additional patent filings. Excluding the investment in inventory in anticipation of clinical trials beginning in 2020 and patents, R&D expenses for 2020 were $112,552 for the three months ended September 30, 2020. During 2019 we did not fund any R&D as a result of its limited resources.

 

Interest Expense and Financing Fees

 

During the three month ended September 30, 2020 we incurred $504,061 in interest expense, compared to $47,462 in the three months period ended September 30, 2019. The increase of $456,599 or approximately 962% was primarily due to the increase in the amortization of the debt discount, debt issuance cost and interest on the 2020 Convertible Notes.

 

Income Taxes

 

Federal income tax expenses for the three months ended September 30, 2020 were $0, as compared to $30,509 for the three months ended September 30, 2019, a decrease of $30,509. The decrease is primarily due to non-recurring income tax expenses in 2019  primarily related to (i) the recognition of Ferring license fee income of $5,000,000, as well as (ii) other book-to-tax adjustments for income tax reporting purposes.

 

Net Loss

 

For the reasons stated above, we had a net loss of $1,771,827 for the three months ended September 30, 2020, compared to a net loss of $710,334 for the three months ended September 30, 2019. The increase of $1,061,493 or approximately 149%, is primarily due to an increase in operating expense, interest expenses and financing fees.  Total non-cash related expenses in the period totaled $837,236, primarily associated with equity-based expensing and debt amortization.

 

Nine months ended September 30, 2020, compared to the nine months ended September 30, 2019

 

Net Sales and Revenues

 

Revenue for the nine months ended September 30, 2020 was $840,714, a decrease compared to $1,151,641 for the nine months ended September 30, 2019. The decrease of $310,927 or 27% was the result of reduced product sales to Ferring, due primarily to the impact of the COVID 19 pandemic in the first half of the year. A majority of clinics curtailed their fertility services, especially in connection with the general lockdowns that occurred. More recently, many of the clinics have resumed operations, albeit at a measured pace.

 

 

Gross Margin

 

The gross margin reported for the nine months ended September 30, 2020 was 91% or $762,152 compared to 90% or $1,040,455 for the nine months ended September 30, 2019.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the nine months ended September 30, 2020 were $4,311,872, compared to $2,087,725 for the nine months ended September 30, 2019. The increase of $2,224,147 or 107% was primarily the result of an increase in personnel, stock-based compensation and other corporate expenses.  Non-cash related operating expenses in the nine-month period totaled $1,334,806 compared to $133,901 in the prior 9-months.

 

Research and Development Expenses

 

We began to fund additional research and development (“R&D”) efforts in 2020 in preparation for our clinical trial, anticipated to occur in 2020, and additional patent filings. Excluding the investment in inventory for the clinical trials and patents, R&D expenses for 2020 were $177,492 for the nine months ended September 30, 2020. During 2019, we did not fund and R&D as a result of our limited resources.

 

Interest Expense and Financing Fees

 

During the nine-month period ended September 30, 2020 we incurred $811,888 in interest expense compared to $332,677 in the nine month ended September 30, 2019. The increase of $479,211 or approximately 144% primarily due to an increase in the amortization of the debt discount, debt issuance cost and interest on the 2020 Convertible Notes.

 

Income Taxes

 

Federal income tax expenses for the nine months ended September 30, 2020 were $0, as compared to $30,509 for the nine months ended September 30, 2019, a decrease of $30,509. The decrease is primarily due to non-recurring income tax expenses in 2019 primarily related to (i) the recognition of Ferring license fee income of $5,000,000, as well as (ii) other book-to-tax adjustments for income tax reporting purposes.

 

Net Loss

 

For the reasons above, we had a net loss of $4,539,100 for the nine months ended September 30, 2020 compared to a net loss of $1,410,456 for the nine months ended September 30, 2019. The increase of $3,128,644 or approximately 222% is primarily due to the increase in operating expenses, interest expenses and financing fees.  Total non-cash related expenses in the nine month period totaled $2,141,082, primarily associated with equity-based expensing and debt amortization compared to $503,466 in the prior nine month period.

 

Liquidity and Capital Resources

 

Our registered independent certified public accountants have stated in their report dated March 30, 2020, filed with our Annual Report on Form 10-K for the year ended December 31, 2019 that we have suffered net losses from operations and have a net capital deficiency.  These factors among others may raise substantial doubt about our ability to continue as a going concern.

 

Our ability to continue as a going concern is dependent on, among other things, our ability to raise additional capital and implement our business plan. Our financial statements attached do not include any adjustments that might be necessary if we are unable to continue as a going concern. We finalized our new distribution and supply agreements with Ferring on January 14, 2019 and as part of the closing process we received a $5 million one-time license payment.

 

To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms, if at all.

 

 

For the nine months ended September 30, 2020 and 2019, we had net losses of $4,539,100 and $1,410,456, respectively. The net loss in 2020 was higher than 2019 due to the increase in operating expenses and interest expenses and financing fees in the nine months ended September 30, 2020. We had working capital deficit of $510,693 in the nine months ended September 30, 2020 verses working capital as of December 31, 2019 of $42,330. As of September 30, 2020, our stockholder’s deficiency was $3,901,944 compared to $3,713,595 as of December 31, 2019 and cash used in operations was $2,954,823 for the nine months ended September 30, 2020 compared to cash provided by operations of $2,141,607 for the nine months ended September 30, 2019. Historically, our primary sources of liquidity have been from equity or debt offerings. Until we can generate a sufficient amount of cash from operations, we expect to finance future cash needs through public or private equity or debt offerings. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly scale back our operations or delay, scale back or discontinue the continuing development of our products. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.

 

The following table shows a summary of our cash flows for the nine months ended September 30, 2020 and 2019:

 

   

2020

   

2019

 

Cash (used in) provided by:

               

Operating activities

    (2,954,823

)

    2,141,607  

Investing activities

    (90,682

)

    (114,706

)

Financing activities

    2,715,209       (229,465

)

 

Net cash as of September 30, 2020, was $908,289, which is $330,296 lower than net cash of $1,238,585 at December 31, 2019.

 

Net cash used in operating activities was $2,954,823 for the nine months ended September 30, 2020, compared to net cash provided by operating activities of $2,141,607 for the nine months ended September 30, 2019.  The increase in net cash used in operations was primarily due to the increase in net loss.

 

The decrease in cash used in investing activities for the nine months ended September 30, 2020 from the nine months ended September 30, 2019 is the result of expenses for the development and purchasing of molds for the next generation of the INVOcell.

 

Cash provided by financing activities was $2,715,209 during the nine months ended September 30, 2020 as a result of proceeds from the 2020 Convertible Notes, offset by repayment of promissory notes with the cash received in this financing. Cash used during the nine months ended September 30, 2019 was used to pay principle on notes payable.

 

Notes Payable and Other Related Party Transactions

 

In April 2011, we issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. We paid $25,000 of the Note in 2011 in cash. The Q211 Note is convertible into our Common Stock at a conversion price of $0.96 per share, subject to adjustments. During the three and nine months ended September 30, 2019, we accrued interest in the amount of $597 and $1,836 on the Q211 Note, respectively.

 

In November 2011, we issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note was converted into our common stock at a conversion price of $0.32 per share, subject to adjustments. During the three and nine months ended September 30, 2019, we accrued interest in the amount of $253 and $749 on the Q411 Note, respectively.

 

The foregoing notes had maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of our common stock original conversion prices of $.96 and $.32, respectively, subject to adjustments upon our  issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.21).

 

 

On August 7, 2019, we sent James Bowdring, a related party, a check in the amount of $65,197 as full payment of the foregoing promissory notes. On August 8, 2019, Mr. Bowdring’s legal counsel returned this check with a letter stating that the check did not properly account for the compound interest identified in such notes. In addition, the letter stated Mr. Bowdring’s desire to convert these promissory notes into shares of our common stock in lieu of any cash payment. We do not believe that Mr. Bowdring has the right to convert such notes upon receiving payment of such notes and intends to vigorously contest any conversion of these notes.

 

In May 2018, we  sold 4,687 shares of common stock at a price of $6.40 per share for proceeds of $30,000 to Charles Mulrey and family, the brother-in-law of Robert J. Bowdring, Director & Acting Chief Financial Officer as part of the recent financing.

 

During the second quarter of 2018, INVO Bioscience settled a commitment it had with one of its Directors, Dr. Kevin Doody for the services he and his team performed prior to and following INVOcell’s FDA clearance related to clinical guidance and support. We issued him 93,750 common shares of stock with a fair value of $1,530,000.

 

We previously rented its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of former Director and former Interim CFO Robert Bowdring, from November 2012 through May 2019 when the Company relocated to a new facility. It was a month to month rental arrangement for less than the going fair market real estate rental rate. The rent expense paid for the nine months ended September 30, 2020 and 2019 was $0 and $1,800 respectively. In addition, we had purchased stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our former corporate office. INVO Bioscience spent $0 and $2,134 with Superior during the three months ended September 30, 2020 and 2019, respectively, and $0 and $8,168 during the nine months ended September 30, 2020 and 2019, respectively.

 

Critical Accounting Policies and Estimates

 

For further discussion of our accounting policies see the “Summary of Significant Accounting Policies” in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on March 30, 2020 as well as the notes to the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to Leases, Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) and subsequent amendments, which replaced existing GAAP and requires lessees to recognize right-of-use (“ROU”) assets and corresponding lease liabilities that depict the rights and obligations arising from a lease agreement. We implemented ASU 2016-02 on January 1, 2019 and elected certain practical expedients available under the ASU. As a result of the adoption, the Company recognized ROU assets totaling $116,441 and lease liabilities totaling $116,441 as of the adoption date. For additional information, see Note 1 to our Unaudited Condensed Consolidated Financial Statements – “Basis of Presentation and Significant Accounting Policies-Recently Issued Accounting Pronouncements” elsewhere in this Quarterly Report.

 

The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 606, when a customer obtains control of promised goods and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods and collectability of the resulting receivable is reasonably assured.

 

Intangible Assets

 

Our intangible assets consist of our INVOcell and INVO process patents. We amortize our intangible assets with definitive lives over their useful lives, which range up to 20 years, based on the time period the Company expects to receive the economic benefit from these assets. No impairment charge was recorded during the nine months  ended September 30, 2020 or 2019.

 

We continually assess whether events or changes in circumstances have occurred that may warrant revision of the estimated useful lives of ours intangible and indefinite-lived assets or whether the remaining balances of those assets should be evaluated for possible impairment. There were no changes in the carrying value of intangible and indefinite-lived assets during the nine months ended September 30, 2020.

 

 

Impairment of Long-Lived Assets

 

Our long-lived assets are our patents which are subject to amortization. We evaluate long-lived assets for recoverability whenever events or changes in circumstances indicate that an asset may have been impaired. In evaluating an asset for recoverability, we estimate the future cash flow expected to result from the use of the asset and eventual disposition. If the expected future undiscounted cash flow is less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying amount over the fair value of the asset, is recognized.

 

We continually assess whether events or changes in circumstances have occurred that may warrant revision of the estimated useful lives of our intangible and indefinite-lived assets or whether the remaining balances of those assets should be evaluated for possible impairment. There were no changes in the carrying value of intangible and indefinite-lived assets during the nine months ended September 30, 2020.

 

Allowance for Doubtful Accounts Receivable

 

We perform ongoing credit evaluations of our customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by our review of their current credit information. We continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon our historical experience and any specific customer collection issues that we have identified. While such credit losses have historically been minimal, within our expectations and the provisions established, we cannot guarantee that we will continue to experience the same credit loss rates that we have in the past. A significant change in the liquidity or financial position of any of our significant customers could have a material adverse effect on the collectability of our accounts receivable and our future operating results.

 

Income Taxes 

 

We use the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, we make a determination as to whether the carryforward will be utilized in the future. Currently, a valuation allowance is established for all deferred tax assets and carryforwards as their recoverability is deemed to be uncertain. If our expectations for future operating results at the federal or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.

 

Income tax expense was $0 and $30,509 for the nine months ended September 30, 2020 and 2019. The annual forecasted effective income tax rate for 2020 is 0% with a year-to-date effective income tax rate for the nine months ended September 30, 2020 of 0%.

 

Recent Accounting Pronouncements

 

For information regarding recent accounting pronouncements and their effect on us, see “Recent Accounting Pronouncements” in Note 2 of the Notes to Unaudited Condensed Consolidated Financial Statements contained herein.

 

 

Forward Looking Statements

 

The statements contained in this Quarterly Report on Form 10-Q which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, the commercialization of our technology, regulatory approvals, our development of new technologies, the adequacy of our ability to develop current financing sources to fund our operations, our growth initiatives, and the strength of our intellectual property portfolio. These forward-looking statements may be identified by the use of words such as “plans”, “intends,” “may,” “could,” “expect,” “estimate,” “anticipate,” “continue” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices from customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to comply with our debt obligations, our ability to deleverage our balance sheet, and seasonality, as well as the uncertainties set forth in the our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020, including the risk factors contained in Item 1A, and from time to time in our other filings with the SEC  We disclaim any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

Item 3.       Quantitative and Qualitative Disclosures about Market Risks

 

Not applicable

 

Item 4.       Controls and Procedures

 

(a)     Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

 

Our management, under the supervision and with the participation of our Chief Executive Officer and Acting Chief Financial  Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act) as of September 30, 2020, the end of the fiscal period covered by this Form 10Q.  We maintain disclosure controls and procedures that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.  Based upon that evaluation, our Chief Executive Officer and Acting Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2020.

 

(b)     Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

 

Item 1.      Legal Proceedings

 

We did not have any material development for any pending litigation in the nine months ended September 30, 2020. Please see our Annual Report on Form 10-K for the year ended December 31, 2019 for a description of pending litigation, which Report is incorporated herein by reference.

 

Item 1A.   Risk Factors

 

You should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition or future results set forth under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on March 30, 2020 with the SEC and our Quarterly Report on Form 10-Q for the period ended June 30, 2020 filed on August 13, 2020 with the SEC. There have been no material changes from the factors disclosed in our 2019 Annual Report on Form 10-K, and our Quarterly Report on Form 10-Q for the period ended June 30, 2020 although we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

We are vulnerable to the general economic effects of epidemics and other public health crises, such as the novel strain of coronavirus (COVID 19) reported to have surfaced in Wuhan, China in 2019. Due to the recent outbreak of the coronavirus, there has been a curtailment of global travel and business activities. More specifically, many fertility clinics around the world reduced or even temporarily postponed new procedures during the initial pandemic wave, and many continue to operate in a reduced capacity.  If not resolved quickly, the impact of the epidemic could have a material adverse effect on our business, financial condition and operating results and general ability to grow and expand INVOcell usage around the world. In particular, our sales and marketing efforts with the INVOcell and INVOcell Procedure could be adversely affected by recently implemented protocols for screening and restricting outside visitors and vendors. Additionally, officially imposed quarantines and self-quarantines could interfere with patients’ ability to see a health care provider and obtain our INVOcell and INVOcell Procedure.

 

Item 2.      Unregistered Issuance of Equity Securities and Use of Proceeds

 

1.

In August 2020, we issued 3,750 shares of common stock with a fair value of $19,500 in consideration of consulting services rendered.  We did not receive any proceeds from the issuance. The issuance was exempt under Section 4(a)(2) of the Securities Act of 1933, as amended.

 

2.

In November 2020, we issued 109 shares of common stock as the result of the rounding on the 5-8 reverse stock split. We did not receive any proceeds from the issuance. The issuance was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended.

 

Item 3.      Defaults Upon Senior Securities

 

None.

 

Item 4.      Mine Safety Disclosures

 

Not applicable

 

 

Item 5.      Other Information

 

1.  See our Current Report on Form 8-K dated November 12, 2020 and filed on November 13, 2020 for details regarding our entry into an underwriting agreement.

 

2.  See our Current Report on Form 8-K dated November 8, 2020 and filed on November 9, 2020 for details regarding our appointment of Jeffrey Segal as a director.

 

3.  See our Current Report on Form 8-K dated November 5, 2020 and filed on November 9, 2020 for details regarding our 5-for-8 reverse stock split.

 

4.  See our Current Report on Form 8-K dated September 24, 2020 and filed on September 30, 2020 for details regarding our joint venture.

 

 

Item 6.      Exhibits

 

1.1

Underwriting Agreement dated November 12, 2020, filed as Exhibit 1.1.to the Registrant’s Current Report on Form 8-K filed on November13, 2020 and incorporated herein by reference.

3.1

Certificate of Change, attached as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated November 5,2020 and filed on November 9, 2020 and incorporated herein by reference.

10.1

Pre-incorporation and Shareholders Agreement, attached as exhibit 10.1 to the Registrant’s Current Report on Form 8-K dated September 30, 2020 and incorporated herein by reference.

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32**

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019, (iii) Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019, and (iv) Notes to Consolidated Financial Statements

 

 

 

*      Filed herewith. 
   
    **    Furnished herewith.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 16, 2020.

 

 

INVO Bioscience, Inc.

 

 

 

 

 

Date:  November 16, 2020

By:

/s/Steven Shum                     

 

 

 

Steven Shum, Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

Date:  November 16, 2020

By:

/s/ Debra Hoopes           

 

 

 

Debra Hoopes, Acting Chief Financial Officer

 

 

 

(Acting Principal Financial and Accounting Officer)

 

 

 

 

 

 

37
EX-31.1 2 ex_213286.htm EXHIBIT 31.1 ex_213286.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Steven Shum, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of INVO Bioscience Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the unaudited condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  

INVO BIOSCIENCE

 

 

 

 

 

Date: November 16, 2020

By:

/s/ Steven Shum                                 

 

 

 

Steven Shum

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 
EX-31.2 3 ex_213287.htm EXHIBIT 31.2 ex_213287.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Debra Hoopes, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of INVO Bioscience Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the unaudited condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

INVO BIOSCIENCE

 

 

 

 

 

Date: November 16, 2020

By:

/s/ Debra Hoopes                           

 

 

 

Debra Hoopes

 

 

 

Acting Chief Financial Officer

(Principal Financial Officer)

 

 

 

 
EX-32 4 ex_213288.htm EXHIBIT 32 ex_213288.htm

 

EXHIBIT 32

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of INVO Bioscience, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Steven Shum, Chief and Principal Executive Officer of the Company, and Debra Hoopes, Acting Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

INVO BIOSCIENCE

 

 

 

 

 

Date: November 16, 2020

By:

/s/ Steven Shum 

 

 

 

Steven Shum

 

 

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

INVO BIOSCIENCE

 

 

 

 

 

Date: November 16, 2020

By:

/s/ Debra Hoopes

 

 

 

Debra Hoopes

 

 

 

Acting Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 

 

 

 

 
EX-101.INS 5 invo-20200930.xml XBRL INSTANCE DOCUMENT 0001417926 2020-01-01 2020-09-30 0001417926 2020-11-16 0001417926 2020-09-30 0001417926 2019-12-31 0001417926 invo:ProductRevenueMember 2020-07-01 2020-09-30 0001417926 invo:ProductRevenueMember 2019-07-01 2019-09-30 0001417926 invo:ProductRevenueMember 2020-01-01 2020-09-30 0001417926 invo:ProductRevenueMember 2019-01-01 2019-09-30 0001417926 us-gaap:LicenseMember 2020-07-01 2020-09-30 0001417926 us-gaap:LicenseMember 2019-07-01 2019-09-30 0001417926 us-gaap:LicenseMember 2020-01-01 2020-09-30 0001417926 us-gaap:LicenseMember 2019-01-01 2019-09-30 0001417926 2020-07-01 2020-09-30 0001417926 2019-07-01 2019-09-30 0001417926 2019-01-01 2019-09-30 0001417926 us-gaap:CommonStockMember 2018-12-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001417926 us-gaap:RetainedEarningsMember 2018-12-31 0001417926 2018-12-31 0001417926 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001417926 2019-01-01 2019-03-31 0001417926 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001417926 us-gaap:CommonStockMember 2019-03-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001417926 us-gaap:RetainedEarningsMember 2019-03-31 0001417926 2019-03-31 0001417926 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001417926 2019-04-01 2019-06-30 0001417926 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001417926 us-gaap:CommonStockMember 2019-06-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001417926 us-gaap:RetainedEarningsMember 2019-06-30 0001417926 2019-06-30 0001417926 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001417926 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001417926 us-gaap:CommonStockMember 2019-09-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001417926 us-gaap:RetainedEarningsMember 2019-09-30 0001417926 2019-09-30 0001417926 us-gaap:CommonStockMember 2019-12-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001417926 us-gaap:RetainedEarningsMember 2019-12-31 0001417926 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001417926 2020-01-01 2020-03-31 0001417926 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001417926 us-gaap:CommonStockMember 2020-03-31 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001417926 us-gaap:RetainedEarningsMember 2020-03-31 0001417926 2020-03-31 0001417926 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001417926 2020-04-01 2020-06-30 0001417926 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001417926 us-gaap:CommonStockMember 2020-06-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001417926 us-gaap:RetainedEarningsMember 2020-06-30 0001417926 2020-06-30 0001417926 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001417926 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001417926 us-gaap:CommonStockMember 2020-09-30 0001417926 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001417926 us-gaap:RetainedEarningsMember 2020-09-30 0001417926 invo:EstimatedUsefulLifeMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2020-01-01 2020-09-30 0001417926 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2020-01-01 2020-09-30 0001417926 us-gaap:EquipmentMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember us-gaap:OfficeEquipmentMember 2020-01-01 2020-09-30 0001417926 srt:MaximumMember us-gaap:OfficeEquipmentMember 2020-01-01 2020-09-30 0001417926 us-gaap:ToolsDiesAndMoldsMember 2020-09-30 0001417926 us-gaap:ToolsDiesAndMoldsMember 2019-12-31 0001417926 us-gaap:EquipmentMember 2020-09-30 0001417926 us-gaap:EquipmentMember 2019-12-31 0001417926 us-gaap:OfficeEquipmentMember 2020-09-30 0001417926 us-gaap:OfficeEquipmentMember 2019-12-31 0001417926 us-gaap:TrademarksMember 2020-01-01 2020-09-30 0001417926 invo:ConvertedAccountPayableToPromissoryNoteMember 2016-08-31 0001417926 invo:ConvertedAccountPayableToPromissoryNoteMember 2016-08-01 2016-08-31 0001417926 invo:ConvertedAccountPayableToPromissoryNoteMember 2020-09-30 0001417926 invo:ConvertedAccountPayableToPromissoryNoteMember 2020-01-01 2020-09-30 0001417926 invo:The2018ConvertibleNotesMember 2018-05-31 0001417926 invo:The2018ConvertibleNotesDueJanuary302021Member 2018-05-31 0001417926 invo:The2018ConvertibleNotesDueMarch312021Member 2018-05-31 0001417926 invo:The2018ConvertibleNotesMember 2018-10-01 2018-12-31 0001417926 invo:PrincipalMember invo:The2018ConvertibleNotesMember 2019-01-01 2019-09-30 0001417926 invo:AccruedInterestMember invo:The2018ConvertibleNotesMember 2019-01-01 2019-09-30 0001417926 invo:The2018ConvertibleNotesMember 2019-01-01 2019-09-30 0001417926 invo:The2018ConvertibleNotesMember 2018-05-31 2018-05-31 0001417926 invo:The2018ConvertibleNotesMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:PrincipalMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:AccruedInterestMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:ConversionDiscountMember 2020-05-01 2020-05-31 0001417926 invo:ConvertibleNotes2020Member 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:NotesHeldByRelatedPartyMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:PrincipalMember invo:NotesHeldByRelatedPartyMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:AccruedInterestMember invo:NotesHeldByRelatedPartyMember 2020-05-01 2020-05-31 0001417926 invo:The2018ConvertibleNotesMember invo:ConversionDiscountMember invo:NotesHeldByRelatedPartyMember 2020-05-01 2020-05-31 0001417926 invo:ConvertibleNotes2020Member 2020-07-31 0001417926 invo:ConvertibleNotes2020Member 2020-05-01 2020-07-31 0001417926 2020-07-31 0001417926 invo:PlacementAgentWarrantsMember invo:ConvertibleNotes2020Member 2020-05-01 2020-07-31 0001417926 invo:PlacementAgentWarrantsMember invo:ConvertibleNotes2020Member 2020-07-31 0001417926 invo:PurchaseOptionFairValueMember invo:ConvertibleNotes2020Member 2020-05-01 2020-07-31 0001417926 invo:ConvertibleNotes2020Member 2020-07-01 2020-09-30 0001417926 invo:ConvertibleNotes2020Member 2019-07-01 2019-09-30 0001417926 invo:ConvertibleNotes2020Member 2020-01-01 2020-09-30 0001417926 invo:ConvertibleNotes2020Member 2019-01-01 2019-09-30 0001417926 2020-06-22 0001417926 invo:PPPLoanMember 2020-06-22 2020-06-22 0001417926 invo:PPPLoanMember 2020-06-22 0001417926 invo:ConvertibleNotes2020Member 2020-09-30 0001417926 invo:ConvertibleNotes2020Member 2019-12-31 0001417926 invo:ConvertibleNotes2020Member us-gaap:StockOptionMember 2020-09-30 0001417926 invo:ConvertibleNotes2020Member us-gaap:StockOptionMember 2019-12-31 0001417926 invo:ConvertibleNotes2020Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2020-09-30 0001417926 invo:ConvertibleNotes2020Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001417926 invo:ConvertibleNotes2020Member 2019-01-01 2019-12-31 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2011-04-30 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2011-01-01 2011-12-31 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-07-01 2019-09-30 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-01-01 2019-09-30 0001417926 invo:Notes2011Member us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2011-11-30 0001417926 invo:Notes2011Member us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-07-01 2019-09-30 0001417926 invo:Notes2011Member us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-01-01 2019-09-30 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-08-07 2019-08-07 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2018-05-31 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-07-01 2020-09-30 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-07-01 2019-09-30 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-01-01 2020-09-30 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-01-01 2019-09-30 0001417926 invo:CharlesMulreyAndFamilyMember 2018-05-01 2018-05-31 0001417926 invo:CharlesMulreyAndFamilyMember 2018-05-31 0001417926 us-gaap:RestrictedStockMember invo:OneOfDirectorsDrKevinDoodyMember 2018-04-01 2018-06-30 0001417926 us-gaap:BuildingMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-01-01 2020-09-30 0001417926 us-gaap:BuildingMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-01-01 2019-09-30 0001417926 us-gaap:BuildingMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-07-01 2020-09-30 0001417926 us-gaap:BuildingMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-07-01 2019-09-30 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-09-30 0001417926 invo:The2018ConvertibleNotesMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-12-31 0001417926 2020-02-19 2020-02-19 0001417926 2020-11-05 2020-11-05 0001417926 2020-10-22 0001417926 invo:Plan2019Member srt:OfficerMember 2020-01-01 2020-01-31 0001417926 invo:Plan2019Member invo:EmployeeMember 2020-02-01 2020-02-28 0001417926 invo:Plan2019Member srt:DirectorMember 2020-02-01 2020-02-28 0001417926 invo:Plan2019Member 2020-02-01 2020-02-29 0001417926 2020-02-01 2020-02-29 0001417926 2020-03-01 2020-03-31 0001417926 2020-05-01 2020-05-31 0001417926 invo:Plan2019Member invo:EmployeeMember 2020-05-01 2020-05-31 0001417926 invo:Plan2019Member 2020-06-01 2020-06-30 0001417926 invo:Plan2019Member invo:EmployeeMember 2020-06-01 2020-06-30 0001417926 invo:Plan2019Member invo:EmployeeMember 2020-08-01 2020-08-31 0001417926 2020-08-01 2020-08-31 0001417926 2019-01-01 2019-01-31 0001417926 2019-02-01 2019-02-28 0001417926 2019-04-01 2019-04-30 0001417926 2019-05-01 2019-05-30 0001417926 2019-08-01 2019-08-31 0001417926 invo:Plan2019Member 2019-10-31 0001417926 invo:Plan2019Member 2020-01-01 2020-01-31 0001417926 srt:MinimumMember invo:Plan2019Member 2019-10-01 2019-10-31 0001417926 srt:MaximumMember invo:Plan2019Member 2019-10-01 2019-10-31 0001417926 invo:Plan2019Member 2020-01-01 2020-09-30 0001417926 invo:Plan2019Member 2020-07-01 2020-09-30 0001417926 invo:Plan2019Member 2019-07-01 2019-09-30 0001417926 invo:Plan2019Member 2019-01-01 2019-09-30 0001417926 invo:Plan2019Member 2020-09-30 0001417926 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001417926 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001417926 us-gaap:RestrictedStockMember 2020-09-30 0001417926 invo:Plan2019Member 2019-10-01 2019-10-31 0001417926 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0001417926 us-gaap:ConvertibleDebtMember 2020-09-30 0001417926 srt:MinimumMember 2018-12-31 0001417926 srt:MaximumMember 2018-12-31 0001417926 srt:MinimumMember 2020-01-01 2020-09-30 0001417926 srt:MaximumMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember 2020-09-30 0001417926 srt:MaximumMember 2020-09-30 0001417926 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001417926 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001417926 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001417926 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember invo:OptionAndWarrantsIssuedWithConvertibleDebtMember 2020-01-01 2020-09-30 0001417926 srt:MaximumMember invo:OptionAndWarrantsIssuedWithConvertibleDebtMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember invo:OptionAndWarrantsIssuedWithConvertibleDebtMember 2020-09-30 0001417926 srt:MaximumMember invo:OptionAndWarrantsIssuedWithConvertibleDebtMember 2020-09-30 0001417926 invo:OptionAndWarrantsIssuedWithConvertibleDebtMember 2020-01-01 2020-09-30 0001417926 srt:MinimumMember 2019-12-31 0001417926 srt:MaximumMember 2019-12-31 0001417926 2019-01-01 2019-12-31 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-08-07 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2020-06-30 0001417926 2019-10-10 2019-10-10 0001417926 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2019-10-10 2019-10-10 0001417926 srt:ChiefOperatingOfficerMember 2017-01-15 2017-01-15 0001417926 srt:ChiefOperatingOfficerMember 2017-01-17 2017-01-17 0001417926 srt:ChiefOperatingOfficerMember 2020-01-17 2020-01-17 0001417926 2019-01-14 2019-01-14 0001417926 2019-01-14 0001417926 invo:SudanUgandaAndEthiopiaMember 2019-09-20 2019-09-20 0001417926 pf0:NG 2019-09-11 2019-09-11 0001417926 pf0:JO 2019-09-19 2019-09-19 0001417926 2020-01-16 2020-01-16 0001417926 invo:DomesticPhysiciansMember 2020-01-01 2020-09-30 0001417926 invo:DomesticPhysiciansMember 2019-01-01 2019-09-30 0001417926 invo:DomesticLicensingDistributionFeeMember 2020-01-01 2020-09-30 0001417926 invo:DomesticLicensingDistributionFeeMember 2019-01-01 2019-09-30 0001417926 invo:INVOCentersArrendondoAndRamirezMember 2020-01-01 2020-09-30 0001417926 us-gaap:OtherInvestmentsMember 2020-01-01 2020-09-30 0001417926 us-gaap:SubsequentEventMember 2020-10-01 2020-11-16 0001417926 us-gaap:SubsequentEventMember 2020-11-12 0001417926 invo:OfferingOptionToUnderwritersMember us-gaap:SubsequentEventMember 2020-11-12 0001417926 us-gaap:SubsequentEventMember 2020-11-12 2020-11-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. false --12-31 Q3 2020 2020-09-30 10-Q 0001417926 false Non-accelerated Filer Yes INVO Bioscience, Inc., false true 4954019 908289 1238585 3699 7558 241484 101387 218667 195910 1372139 1543440 106000 93055 5879 7234 84953 101883 87347 49867 32674 0 210853 158984 1688992 1795479 455978 371530 532592 393017 714286 714286 22356 21365 157620 0 0 912 1882832 1501110 64436 81494 3035714 3571429 607521 325784 0 28824 433 433 5590936 5509074 0 0 495 489 24525427 20174682 -28427866 -23888766 -3901944 -3713595 1688992 1795479 49730 42147 71843 70488 0.0001 0.0001 100000000 100000000 0 0 0 0 0.0001 0.0001 200000000 200000000 4953910 4884879 4953910 4884879 157500 125000 305000 615927 178571 178571 535714 535714 336071 303571 840714 1151641 27398 44926 78562 111186 308673 258645 762152 1040455 112552 0 177492 1463887 891008 4311872 2087725 1576439 891008 4489364 2087725 -1267766 -632363 -3727212 -1047270 504061 47462 811888 332677 -504061 -47462 -811888 -332677 -1771827 -679825 -4539100 -1379947 0 30509 0 30509 -1771827 -710334 -4539100 -1410456 -0.36 -0.15 -0.92 -0.29 -0.36 -0.15 -0.92 -0.29 4946125 4861377 4932405 4847074 4946125 4861377 4932405 4847074 4821641 482 18996517 -21721222 -2724223 1875 26600 26600 8394 1 53722 53723 -458570 -458570 4831910 483 19076839 -22179792 -3102470 28907 3 184997 185000 -241552 -241552 4860817 486 19261836 -22421344 -3159022 1562 15000 15000 93750 93750 -710334 4862379 486 19370586 -23131678 -3760606 4884879 489 20174682 -23888766 40569 4 303459 303463 5001 38000 38000 381475 381475 -1444392 -1444392 4930449 493 20897616 -25333158 -4435049 3437 42509 42509 3750 1 22799 22800 214915 214915 1879542 1879542 24 -1322881 -1322881 4937660 494 23057381 -26656039 -3598164 12500 1 54702 54703 3750 19500 19500 255797 255797 1244363 1244363 106316 106316 -1771827 4953910 495 24525427 -28427866 80300 36600 400675 0 0 -93750 852187 0 465525 297058 59324 0 71430 0 81764 0 16930 9067 8938 7126 -3859 -198878 140097 25817 22757 -56871 84448 20498 -16067 -8456 -535715 4458366 34870 -55553 139575 -1566834 -912 30509 -2954823 2141607 20528 64839 37480 49867 32674 0 -90682 -114706 2998905 0 157620 0 40000 97743 295000 131722 106316 0 2715209 -229465 -330296 1797436 212243 2009679 83134 84043 1062 912 0 116441 0 238723 0 5000 1208163 0 868985 0 999464 0 47293 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note 1 &#x2013; Basis of Presentation</b></p><br/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The accompanying unaudited condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, the condensed consolidated statements of operations and stockholders&#x2019; deficiency for the three and nine months ended September 30, 2020 and 2019, &#xa0;and condensed consolidated statement of cash flows for the nine months ended September 30, 2020 and 2019 of&#xa0;INVO Bioscience, Inc. (the &#x201c;Company&#x201d;), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company&#x2019;s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.</p><br/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company&#x2019;s annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31,2019 previously filed by the Company with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 30, 2020.</p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of September 30, 2020, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form&#xa0;10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form&#xa0;10-Q with the SEC.</p><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note 2 &#x2013; Recent Accounting Pronouncements</b></p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Changes to GAAP are established by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) in the form of accounting standards updates (&#x201c;ASUs&#x201d;) to the FASB&#x2019;s Accounting Standards Codification.</p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company&#x2019;s consolidated financial position and results of operations.</p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>Recently Adopted Accounting Pronouncements</b></i>&#xa0;</p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In February 2016, FASB issued ASU 2016-02, Leases (&#x201c;ASU 2016-02&#x201d;). The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement.&#xa0; The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company&#x2019;s consolidated financial statements.&#xa0;</p><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note 3 &#x2013; Going Concern</b></p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On January 14, 2019, the Company entered into a distribution agreement (the &#x201c;Distribution Agreement&#x201d;) with Ferring International Center S.A. (&#x201c;Ferring&#x201d;) which granted Ferring an exclusive licensing rights to sublicense the Company&#x2019;s patented INVOcell together with the retention device for the U.S. market. Under the terms of the Distribution Agreement, Ferring made an initial cash payment to the Company of $5,000,000 upon the execution of the Ferring distribution agreement in January 2019.&#xa0;</p><br/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">For the nine months ended September 30, 2020 and 2019, the Company had net losses of $4,539,100 and $1,410,456, respectively. The Company had a working capital deficit of $510,693 as of &#xa0;September 30, 2020, compared to working capital of $42,330 as of December 31, 2019. As of September 30, 2020, the Company&#x2019;s stockholder&#x2019;s deficiency was $3,901,944 compared to $3,713,595 as of December 31, 2019 and cash used in operations was $2,954,823 for the nine months ended September 30, 2020 compared to cash provided by operations of $2,141,607 for the nine months ended September 30, 2019. Those factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.</p><br/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Based on the Company&#x2019;s projected cash needs, it will be dependent on generating sufficient sales, entering into new distribution agreements, or&#xa0;raising additional debt or equity capital to support the Company&#x2019;s plans over the next 12 months.&#xa0;&#xa0;&#xa0;</p><br/></div> -510693 42330 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note 4 &#x2013; Inventory</b></p><br/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of September 30, 2020, and December 31, 2019, the Company recorded the following inventory balances:</p><br/><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2316" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td colspan="2" id="new_id-2317" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>September 30,</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2020</b></p> </td> <td id="new_id-2318" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td> <td id="new_id-2319" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td colspan="2" id="new_id-2320" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>December 31,</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2019</b></p> </td> <td id="new_id-2321" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Raw Materials</p> </td> <td id="new_id-2322" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2323" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2324" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,363</td> <td id="new_id-2325" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2326" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2327" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2328" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,333</td> <td id="new_id-2329" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Work in Process</p> </td> <td id="new_id-2330" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2331" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2332" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,823</td> <td id="new_id-2333" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2334" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2335" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2336" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,502</td> <td id="new_id-2337" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Finished Goods</p> </td> <td id="new_id-2338" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2339" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td> <td id="new_id-2340" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127,298</td> <td id="new_id-2341" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2342" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2343" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td> <td id="new_id-2344" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,552</td> <td id="new_id-2345" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Total&#xa0;Inventory</b></p> </td> <td id="new_id-2346" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2347" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2348" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>241,484</b></td> <td id="new_id-2349" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2350" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2351" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td id="new_id-2352" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>101,387</b></td> <td id="new_id-2353" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> </table><br/></div> <div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; "> <div>As of September 30, 2020, and December 31, 2019, the Company recorded the following inventory balances:</div><br/><br/><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2316" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td colspan="2" id="new_id-2317" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>September 30,</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2020</b></p> </td> <td id="new_id-2318" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td> <td id="new_id-2319" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td colspan="2" id="new_id-2320" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>December 31,</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2019</b></p> </td> <td id="new_id-2321" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Raw Materials</p> </td> <td id="new_id-2322" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2323" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2324" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,363</td> <td id="new_id-2325" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2326" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2327" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-2328" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,333</td> <td id="new_id-2329" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Work in Process</p> </td> <td id="new_id-2330" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2331" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2332" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,823</td> <td id="new_id-2333" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2334" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2335" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2336" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,502</td> <td id="new_id-2337" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Finished Goods</p> </td> <td id="new_id-2338" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2339" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td> <td id="new_id-2340" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127,298</td> <td id="new_id-2341" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td> <td id="new_id-2342" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td> <td id="new_id-2343" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td> <td id="new_id-2344" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,552</td> <td id="new_id-2345" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; white-space: nowrap;">&#xa0;</td>